{"filing":{"accession":"0001366074-26-000002","url":"/filing/0001366074-26-000002","form_type":"4","issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_name_source":null,"issuer_ticker":"INBX","issuer_url":"/issuer/0002007919","period_of_report":"2026-09-08","filed_date":"2026-09-08","acceptance_dt":"2026-09-08T16:04:45+00:00","acceptance_label":"2026-09-08 16:04 UTC","ingested_at":"2026-09-09T05:23:16.080847+00:00","ingested_label":"2026-09-09 05:23 UTC","schema_version":null,"source":"Layline","parse_status":"parsed","parse_ok":true,"amends_accession":null,"amends_tier":null,"edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0001366074-26-000002-index.htm","day_url":"/filings/2026-09-08"},"owners":[{"owner_cik":"0001366074","owner_name":"Lappe Mark","url":"/insider/0001366074","anchor":"owner-0001366074","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","is_director":true,"is_officer":true,"is_ten_percent":false,"is_other":false,"filing_anchor":"/filing/0001366074-26-000002#owner-0001366074"}],"line_owners":[{"owner_name":"Lappe Mark","role":"Director, Officer (Chief Executive Officer)"}],"transactions":[{"id":9305809,"accession":"0001366074-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001366074-26-000002","line_url":"/filing/0001366074-26-000002#line-1","is_derivative":false,"issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0002007919","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","filing_role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":1,"other_reporting_owners":0,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5895.0,"shares_display":"5,895","price_per_share":99.2948,"price_display":"99.29","price_state":"stated","total_value":585342.846,"total_display":"585,342.85","total_whole":"585,343","shares_owned_after":711443.0,"shares_owned_after_display":"711,443","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-09-08","filed_date":"2026-09-08","scope":"global","indirect_nature":"By the Lappe Family Trust","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9305808,"accession":"0001366074-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001366074-26-000002","line_url":"/filing/0001366074-26-000002#line-2","is_derivative":false,"issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0002007919","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","filing_role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":1,"other_reporting_owners":0,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6605.0,"shares_display":"6,605","price_per_share":100.6388,"price_display":"100.64","price_state":"stated","total_value":664719.274,"total_display":"664,719.27","total_whole":"664,719","shares_owned_after":718048.0,"shares_owned_after_display":"718,048","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-09-08","filed_date":"2026-09-08","scope":"global","indirect_nature":"By the Lappe Family Trust","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9305807,"accession":"0001366074-26-000002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001366074-26-000002","line_url":"/filing/0001366074-26-000002#line-3","is_derivative":false,"issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0002007919","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","filing_role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":1,"other_reporting_owners":0,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1100.0,"shares_display":"1,100","price_per_share":107.1239,"price_display":"107.12","price_state":"stated","total_value":117836.29,"total_display":"117,836.29","total_whole":"117,836","shares_owned_after":719148.0,"shares_owned_after_display":"719,148","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-09-08","filed_date":"2026-09-08","scope":"global","indirect_nature":"By the Lappe Family Trust","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9305806,"accession":"0001366074-26-000002","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001366074-26-000002","line_url":"/filing/0001366074-26-000002#line-4","is_derivative":false,"issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0002007919","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","filing_role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":1,"other_reporting_owners":0,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":108.235,"price_display":"108.24","price_state":"stated","total_value":54117.5,"total_display":"54,117.50","total_whole":"54,118","shares_owned_after":719648.0,"shares_owned_after_display":"719,648","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-09-08","filed_date":"2026-09-08","scope":"global","indirect_nature":"By the Lappe Family Trust","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9305805,"accession":"0001366074-26-000002","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001366074-26-000002","line_url":"/filing/0001366074-26-000002#line-5","is_derivative":false,"issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0002007919","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","filing_role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":1,"other_reporting_owners":0,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1219.0,"shares_display":"1,219","price_per_share":111.8805,"price_display":"111.88","price_state":"stated","total_value":136382.3295,"total_display":"136,382.33","total_whole":"136,382","shares_owned_after":720867.0,"shares_owned_after_display":"720,867","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-09-08","filed_date":"2026-09-08","scope":"global","indirect_nature":"By the Lappe Family Trust","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null},{"id":9305804,"accession":"0001366074-26-000002","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001366074-26-000002","line_url":"/filing/0001366074-26-000002#line-6","is_derivative":false,"issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0002007919","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","filing_role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":1,"other_reporting_owners":0,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9681.0,"shares_display":"9,681","price_per_share":112.2819,"price_display":"112.28","price_state":"stated","total_value":1087001.0739,"total_display":"1,087,001.07","total_whole":"1,087,001","shares_owned_after":730548.0,"shares_owned_after_display":"730,548","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-09-08","filed_date":"2026-09-08","scope":"global","indirect_nature":"By the Lappe Family Trust","deemed_execution_date":null,"conversion_or_exercise_price":null,"exercise_date":null,"expiration_date":null,"underlying_security_title":null,"underlying_shares":null,"equity_swap_involved":null,"footnote_ids":null}],"n_transactions":6,"line_constants":{"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true},"provenance":{"source_pass":"Layline","parse_status":"parsed","schema_version":null,"retrieved_at":"2026-09-09T05:23:16.080847+00:00","retrieved_label":"2026-09-09 05:23 UTC","primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/0001366074-26-000002-index.htm","accepted_at":"2026-09-08T16:04:45+00:00","accepted_label":"2026-09-08 16:04 UTC"},"related":[{"accession":"0001366268-26-000004","url":"/filing/0001366268-26-000004","form_type":"4","issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_name_source":null,"issuer_ticker":"INBX","issuer_url":"/issuer/0002007919","period_of_report":"2026-09-08","filed_date":"2026-09-08","acceptance_dt":"2026-09-08T17:23:30+00:00","acceptance_label":"2026-09-08 17:23 UTC","ingested_at":"2026-09-09T05:23:16.080847+00:00","ingested_label":"2026-09-09 05:23 UTC","schema_version":null,"source":"Layline","parse_status":"parsed","parse_ok":true,"amends_accession":null,"amends_tier":null,"edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0001366268-26-000004-index.htm","day_url":"/filings/2026-09-08"},{"accession":"0001240801-26-000004","url":"/filing/0001240801-26-000004","form_type":"4","issuer_cik":"0002007919","issuer_name":"Inhibrx Biosciences, Inc.","issuer_name_source":null,"issuer_ticker":"INBX","issuer_url":"/issuer/0002007919","period_of_report":"2026-09-08","filed_date":"2026-09-08","acceptance_dt":"2026-09-08T16:26:03+00:00","acceptance_label":"2026-09-08 16:26 UTC","ingested_at":"2026-09-09T05:23:16.080847+00:00","ingested_label":"2026-09-09 05:23 UTC","schema_version":null,"source":"Layline","parse_status":"parsed","parse_ok":true,"amends_accession":null,"amends_tier":null,"edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0001240801-26-000004-index.htm","day_url":"/filings/2026-09-08"}],"related_rule":"Other filings held for the same issuer and the same period of report. This is a heuristic match on issuer and period, not the amendment link: any amendment relation this catalog holds is stated above, with the confidence it was derived at.","amendment":{},"canonical_url":"https://ebomi.com/filing/0001366074-26-000002","retrieved_at":"2026-09-09T10:04:39+00:00","coverage":{"filings":1506293,"transactions":4300629,"issuers":17686,"insiders":168555,"first_filed_date":"2003-06-30","last_filed_date":"2026-09-08","last_ingest":"2026-09-09T05:23:16.080847+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"exact","insiders":"exact"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","code":"MIT","code_url":"https://spdx.org/licenses/MIT.html","grant":"CC-BY-4.0","grant_url":"https://creativecommons.org/licenses/by/4.0/","grant_note":"ebomi's own layer, the parsed and normalised records and this presentation, is released under CC BY 4.0. Attribution is the citation_request below. The software is released under the MIT License.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.7910/DVN/VH6GVH","bulk_alternative_url":"https://doi.org/10.7910/DVN/VH6GVH","cite_as":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023). doi:10.1038/s41597-023-02147-6"}}